← Back to Search

Hormone Therapy

Tamoxifen 20 mg for Tumors

Phase 2
Recruiting
Led By Jonathan Strosberg, MD
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests whether tamoxifen can help treat patients with neuroendocrine tumors that have progressed despite positive estrogen or progesterone expression.

Eligible Conditions
  • Tumors
  • Neuroendocrine Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Disease control rate
Incidence of Treatment-related Adverse Events
Progression-free survival
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: TamoxifenExperimental Treatment1 Intervention
The participants will receive tamoxifen 20mg orally once daily with a glass of water. Each cycle will be defined for 42 days (6 weeks).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tamoxifen 20 mg
2013
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
561 Previous Clinical Trials
144,815 Total Patients Enrolled
1 Trials studying Tumors
9 Patients Enrolled for Tumors
Jonathan Strosberg, MDPrincipal InvestigatorMoffitt Cancer Center
4 Previous Clinical Trials
167 Total Patients Enrolled
~2 spots leftby Nov 2025